Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eyenovia, Arctic Vision enter exclusive collaboration for MicroPine, MicroLine » 08:28
08/11/20
08/11
08:28
08/11/20
08:28
EYEN

Eyenovia

$3.60 /

+0.195 (+5.73%)

Eyenovia and Arctic…

Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China and South Korea. Under the terms of the agreement, Eyenovia may receive up to a total of $45.75M in upfront payments as well as additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. In addition, Arctic Vision will purchase its supply of MicroPine and MicroLine from Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. Eyenovia will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to its Asian licensee pursuant to the arrangement by which Eyenovia reacquired rights to such products in Greater China and South Korea from the original licensee.

ShowHide Related Items >><<
EYEN Eyenovia
$3.60 /

+0.195 (+5.73%)

EYEN Eyenovia
$3.60 /

+0.195 (+5.73%)

03/26/20 H.C. Wainwright
Eyenovia price target lowered to $6 from $10 at H.C. Wainwright
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
10/30/19 H.C. Wainwright
Eyenovia price target lowered to $10 from $12 at H.C. Wainwright
EYEN Eyenovia
$3.60 /

+0.195 (+5.73%)

Yesterday
Initiation
J.B. Hunt initiated with an Outperform at Evercore ISI » 06:38
08/10/20
08/10
06:38
08/10/20
06:38
JBHT

J.B. Hunt

$135.93 /

+2.085 (+1.56%)

Evercore ISI analyst…

Evercore ISI analyst Jonathan Chappell initiated coverage of J.B. Hunt with an Outperform rating.

ShowHide Related Items >><<
JBHT J.B. Hunt
$135.93 /

+2.085 (+1.56%)

JBHT J.B. Hunt
$135.93 /

+2.085 (+1.56%)

07/20/20 Argus
J.B. Hunt price target raised to $155 from $115 at Argus
07/17/20
Fly Intel: Top five analyst upgrades
07/17/20 BMO Capital
J.B. Hunt price target raised to $125 from $100 at BMO Capital
07/17/20 Baird
J.B. Hunt price target raised to $148 from $128 at Baird
JBHT J.B. Hunt
$135.93 /

+2.085 (+1.56%)

JBHT J.B. Hunt
$135.93 /

+2.085 (+1.56%)

JBHT J.B. Hunt
$135.93 /

+2.085 (+1.56%)

Over a week ago
Conference/Events
William Blair to hold a virtual conference » 09:55
08/04/20
08/04
09:55
08/04/20
09:55
RCUS

Arcus Biosciences

$20.42 /

-0.61 (-2.90%)

, AGEN

Agenus

$3.20 /

-0.055 (-1.69%)

, EXEL

Exelixis

$23.06 /

-0.64 (-2.70%)

, CALA

Calithera Biosciences

$4.85 /

-0.02 (-0.41%)

, RGEN

Repligen

$155.50 /

-3.02 (-1.91%)

, PIRS

Pieris Pharmaceuticals

$2.68 /

-0.025 (-0.92%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$32.33 /

-0.92 (-2.77%)

, CLLS

Cellectis

$17.44 /

+ (+0.00%)

, AUTL

Autolus Therapeutics

$13.92 /

+ (+0.00%)

, GRTS

Gritstone Oncology

$3.35 /

+0.03 (+0.90%)

, ADPT

Adaptive Biotechnologies

$39.49 /

+0.12 (+0.30%)

, TBIO

Translate Bio

$15.60 /

-0.14 (-0.89%)

, EBS

Emergent BioSolutions

$122.01 /

+4.045 (+3.43%)

, ITCI

Intra-Cellular

$20.77 /

-0.15 (-0.72%)

, KRTX

Karuna Therapeutics

$86.82 /

-0.68 (-0.78%)

, ASMB

Assembly Biosciences

$23.15 /

+0.03 (+0.13%)

, NCNA

NuCana

$6.55 /

+0.4 (+6.50%)

, AXSM

Axsome Therapeutics

$74.50 /

-1.82 (-2.38%)

, OVID

Ovid Therapeutics

$6.61 /

-0.16 (-2.36%)

, ALLK

Allakos

$78.92 /

-0.57 (-0.72%)

, NBIX

Neurocrine

$124.09 /

+0.92 (+0.75%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+ (+0.00%)

, CRSP

Crispr Therapeutics

$91.70 /

-0.85 (-0.92%)

, BEAM

Beam Therapeutics

$19.00 /

+0.03 (+0.16%)

, GBT

Global Blood Therapeutics

$68.59 /

-2.08 (-2.94%)

, IONS

Ionis Pharmaceuticals

$58.45 /

-0.78 (-1.32%)

, RTRX

Retrophin

$20.19 /

+ (+0.00%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.20 /

-0.055 (-1.69%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$155.50 /

-3.02 (-1.91%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+ (+0.00%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.55 /

+0.4 (+6.50%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$78.92 /

-0.57 (-0.72%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+ (+0.00%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

Conference/Events
William Blair to hold a virtual conference » 08:49
08/04/20
08/04
08:49
08/04/20
08:49
RCUS

Arcus Biosciences

$21.03 /

+1.34 (+6.81%)

, AGEN

Agenus

$3.25 /

+0.205 (+6.73%)

, EXEL

Exelixis

$23.70 /

+0.64 (+2.78%)

, CALA

Calithera Biosciences

$4.87 /

+0.15 (+3.18%)

, RGEN

Repligen

$158.52 /

+7.46 (+4.94%)

, PIRS

Pieris Pharmaceuticals

$2.71 /

+0.135 (+5.25%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$33.25 /

+2 (+6.40%)

, CLLS

Cellectis

$17.44 /

+1.77 (+11.30%)

, AUTL

Autolus Therapeutics

$13.92 /

+0.72 (+5.45%)

, GRTS

Gritstone Oncology

$3.32 /

+0.115 (+3.59%)

, ADPT

Adaptive Biotechnologies

$39.37 /

+1.99 (+5.32%)

, TBIO

Translate Bio

$15.74 /

+0.56 (+3.69%)

, EBS

Emergent BioSolutions

$117.97 /

+6.755 (+6.07%)

, ITCI

Intra-Cellular

$20.92 /

+1.11 (+5.60%)

, KRTX

Karuna Therapeutics

$87.50 /

+5.89 (+7.22%)

, ASMB

Assembly Biosciences

$23.12 /

+0.9 (+4.05%)

, NCNA

NuCana

$6.15 /

+0.65 (+11.82%)

, AXSM

Axsome Therapeutics

$76.32 /

+4.97 (+6.97%)

, OVID

Ovid Therapeutics

$6.77 /

+0.32 (+4.96%)

, ALLK

Allakos

$79.49 /

+4.36 (+5.80%)

, NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+0.55 (+5.02%)

, CRSP

Crispr Therapeutics

$92.55 /

+7.15 (+8.37%)

, BEAM

Beam Therapeutics

$18.97 /

-0.31 (-1.61%)

, GBT

Global Blood Therapeutics

$70.67 /

+3.24 (+4.80%)

, IONS

Ionis Pharmaceuticals

$59.23 /

+1.7 (+2.95%)

, RTRX

Retrophin

$20.19 /

+0.385 (+1.94%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.25 /

+0.205 (+6.73%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$158.52 /

+7.46 (+4.94%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.15 /

+0.65 (+11.82%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$79.49 /

+4.36 (+5.80%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

Earnings
Medical Properties Trust sees FY20 normalized FFO $1.68-$1.71, consensus $1.54  08:35
07/30/20
07/30
08:35
07/30/20
08:35
MPW

Medical Properties Trust

$20.30 /

+0.605 (+3.07%)

 
ShowHide Related Items >><<
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

07/10/20
Fly Intel: Top five analyst downgrades
07/10/20 Deutsche Bank
Medical Properties Trust downgraded to Hold from Buy at Deutsche Bank
07/10/20 Deutsche Bank
Medical Properties Trust downgraded to Hold from Buy at Deutsche Bank
04/23/20 Truist
SunTrust lowers price targets on select healthcare REITS
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

  • 06
    Nov
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

Earnings
Medical Properties Trust reports Q2 normalized FFO 38c, consensus 38c » 08:34
07/30/20
07/30
08:34
07/30/20
08:34
MPW

Medical Properties Trust

$20.30 /

+0.605 (+3.07%)

Reports Q2 revenue…

Reports Q2 revenue $291.84M, consensus $309.84M. "As we have previously mentioned, MPT continues to see tremendous potential for further investment. The pandemic the world is going through has created even more opportunities for us," said Edward Aldag, Jr., MPT's chairman, president, and CEO. "During the past three months we have been able to execute on some of those transactions bringing our total 2020 investments to date to $3.1 billion. Between now and the end of the year, we expect to be able to capitalize on other opportunities as well."

ShowHide Related Items >><<
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

07/10/20
Fly Intel: Top five analyst downgrades
07/10/20 Deutsche Bank
Medical Properties Trust downgraded to Hold from Buy at Deutsche Bank
07/10/20 Deutsche Bank
Medical Properties Trust downgraded to Hold from Buy at Deutsche Bank
04/23/20 Truist
SunTrust lowers price targets on select healthcare REITS
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

  • 06
    Nov
MPW Medical Properties Trust
$20.30 /

+0.605 (+3.07%)

Earnings
Arrow Electronics sees Q3 adj. EPS $1.54-$1.70, consensus $145 » 08:13
07/30/20
07/30
08:13
07/30/20
08:13
ARW

Arrow Electronics

$68.76 /

+1.79 (+2.67%)

Sees Q3 revenue…

Sees Q3 revenue $6.33B-$6.93B, consensus $6.5B.

ShowHide Related Items >><<
ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

07/13/20 Citi
Analog/Maxim deal positive for Arrow Electronics, negative for Avnet, says Citi
06/25/20 Longbow
Longbow cuts second half estimates for semis and components
04/28/20 BofA
Arrow Electronics upgraded to Neutral from Underperform at BofA
04/28/20 BofA
Arrow Electronics upgraded to Neutral from Underperform at BofA
ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

Earnings
Arrow Electronics reports Q2 adj. EPS $1.59, consensus $1.45 » 08:12
07/30/20
07/30
08:12
07/30/20
08:12
ARW

Arrow Electronics

$68.76 /

+1.79 (+2.67%)

Reports Q2 revenue…

Reports Q2 revenue $6.61B, consensus $6.37B. "Arrow has again proven to be a source of reliability and stability for suppliers and customers amidst supply chain disruptions and an uncertain economic backdrop. Our efforts to expand our engineering and design expertise both prior to and during the COVID-19 pandemic are helping customers quickly get back to business," said Michael Long, chairman, president, and CEO. "In turn, our vital position in the technology ecosystem, and our ever-expanding capabilities drove results above our expectations. Arrow is harnessing data from billions of transactions with thousands of customers to sell and deliver the products and solutions that our customers want when they need them," continued Mr. Long. "Sales were above the high end of our expectation driven by Asia that has seen a remarkable rebound in manufacturing activity due to earlier pandemic onset and recovery. In terms of product segments, demand remains strong for the software, cloud, and security solutions needed to enable business continuity and remote working," said Mr. Long. "We continue to evolve our portfolio to areas with greater long-term growth potential. With financial returns improving and the effective management of our balance sheet and cash flow, we enhanced our commitment to returning excess cash to shareholders through a new $600 million repurchase authorization," said Chris Stansbury, senior vice president and chief financial officer. "Our liquidity position remains the best in our company's history and improved further, with more than $3.2 billion of undrawn committed borrowing capacity in addition to cash on hand."

ShowHide Related Items >><<
ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

07/13/20 Citi
Analog/Maxim deal positive for Arrow Electronics, negative for Avnet, says Citi
06/25/20 Longbow
Longbow cuts second half estimates for semis and components
04/28/20 BofA
Arrow Electronics upgraded to Neutral from Underperform at BofA
04/28/20 BofA
Arrow Electronics upgraded to Neutral from Underperform at BofA
ARW Arrow Electronics
$68.76 /

+1.79 (+2.67%)

Earnings
Repligen sees FY20 adj. EPS $1.24-$1.29, consensus $1.13 » 07:40
07/30/20
07/30
07:40
07/30/20
07:40
RGEN

Repligen

$138.74 /

+1.53 (+1.12%)

Sees 2020 revenue…

Sees 2020 revenue $332M-$340M, consensus $317.04M.

ShowHide Related Items >><<
RGEN Repligen
$138.74 /

+1.53 (+1.12%)

RGEN Repligen
$138.74 /

+1.53 (+1.12%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
RGEN Repligen
$138.74 /

+1.53 (+1.12%)

Earnings
Repligen reports Q2 adj. EPS 42c, consensus 27c » 07:39
07/30/20
07/30
07:39
07/30/20
07:39
RGEN

Repligen

$138.74 /

+1.53 (+1.12%)

Reports Q2 revenue…

Reports Q2 revenue $87.5M, consensus $78.38M. Tony J. Hunt, President and Chief Executive Officer said, "I'm pleased to report that the company delivered outstanding financial performance during the second quarter as we continue to focus on keeping all our manufacturing sites fully operational and managing our supply chain and logistics while also prioritizing the health and safety of our employees. During the second quarter, we saw increased demand in all of our product franchises, highlighted by strong growth in Asia and a significant pick up in orders both in the quarter and into the second half of 2020 related to COVID-19 vaccine and therapeutic programs. We finished the quarter by announcing our acquisition of Engineered Molding Technology, which closed in July, to enhance our single-use portfolio. We are confident about the full year outlook for the company and are updating guidance to reflect our expectations for margin expansion and revenue growth in the range of 23%-26%.".

ShowHide Related Items >><<
RGEN Repligen
$138.74 /

+1.53 (+1.12%)

RGEN Repligen
$138.74 /

+1.53 (+1.12%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
RGEN Repligen
$138.74 /

+1.53 (+1.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.